Cardiogenic shock (CS) is a rapidly progressive, multifactorial syndrome characterized by inadequate tissue perfusion due to primary cardiac pump failure.1 It remains the leading cause of in-hospital mortality in patients with acute myocardial infarction (AMI) and is increasingly recognized in people with acute and chronic heart failure (HF). Despite incremental advances in pharmacological therapies and temporary mechanical circulatory support (tMCS), short- and intermediate-term mortality remains high, exceeding 40%–50% in most registries.
Blumer et al. (Sun,) studied this question.